Phase 1 study of latozinemab in progranulin-associated frontotemporal dementia.

ABSTRACT:

Introduction

Heterozygous mutations in the GRN gene lead to reduced progranulin (PGRN) levels in plasma and cerebrospinal fluid (CSF) and are causative of frontotemporal dementia (FTD) with > 90% penetrance. Latozinemab is a human monoclonal immunoglobulin G1 antibody that is being developed to increase PGRN levels in individuals with FTD caused by heterozygous loss-of-function GRN mutations.

Methods

A first-in-human phase 1 study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple-dose intravenous administration of latozinemab in eight symptomatic participants with FTD caused by a heterozygous loss-of-function GRN mutation (FTD-GRN).

Results

Latozinemab demonstrated favorable saf

SUBMITTER: Ward M 

PROVIDER: S-EPMC10865485 | biostudies-literature | 2024 Jan-Mar

REPOSITORIES: biostudies-literature